Corton Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Corton Capital’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-22,301	Closed	-$971K	–	668
2023 Q3	$971K	Buy	22,301 +9,951	+81%	+$355K	0.49%	21
2023 Q2	$446K	Buy	12,350 +4,329	+54%	+$178K	0.21%	120
2023 Q1	$298K	Buy	+8,021	New	+$361K	0.21%	154
2022 Q4	–	Sell	-4,783	Closed	-$334K	–	387
2022 Q3	$334K	Sell	4,783 -624	-12%	-$46.2K	0.41%	86
2022 Q2	$363K	Buy	5,407 +2,329	+76%	+$148K	0.34%	104
2022 Q1	$253K	Buy	+3,078	New	+$315K	0.11%	282

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Corton Capital's MRTX Position: Q4 2023 in Review

Corton Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 22,301 shares — an estimated $971K sold.

Corton Capital first reported a position in MRTX in Q1 2022 and held it in 6 quarters. The position peaked at $971K in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Corton Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Corton Capital sold 22,301 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $971K.
Corton Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Corton Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $971K in Q3 2023.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Corton Capital's 13F filing for Q4 2023, filed 14 Feb 2024.